By Bhanvi Satija LONDON, Feb 2 (Reuters) - French drugmaker Sanofi said on Monday that its experimental genetic disorder ...

Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the ...

Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher diseaseIn the LEAP2MONO phase 3 study, venglustat, dosed ...

Venglustat is designed to reduce the toxic buildup, and the new trial showed that a daily dose of the drug achieved ...

Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, ...

The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Ocular Therapeutix shares are trading higher Thursday after reports suggested Sanofi is preparing a revised bid for the company.

The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the ...

Sanofi (SNY) shares traded slightly lower in Paris on Thursday even as the French drugmaker reported higher-than-expected ...

A federal judge trimmed a lawsuit that accuses Sanofi of cornering the market for an injectable form of a diabetes drug, ...

By Bhanvi Satija LONDON, Jan 29 (Reuters) - France's Sanofi, among the world's largest vaccine makers, said on Thursday that its vaccines sales would be "slightly negative" this year, partly due to U.